The Post-Ozempic Economy? 2 Industries Bracing for a Slimmer, Less Hungry America

The article argues GLP-1 weight-loss drugs are reshaping consumer spending, creating a headwind for restaurants like Chipotle, whose same-store sales have been flat or negative for four quarters and whose stock is down 50% from highs. By contrast, Planet Fitness is presented as a beneficiary, with 2025 same-club sales up 6.7%, 1.1 million new members, and 2026 guidance for 180 to 190 new club openings and 4% to 5% same-club sales growth. The piece is more investment commentary than hard news, but it highlights a potentially durable shift in demand across consumer sectors.

Analysis

The market is likely underestimating how GLP-1 adoption changes category economics via frequency, not just basket size. If calorie intake structurally falls, the first-order hit is to traffic-dependent dining concepts, but the second-order effect is even more important: vendors optimized for indulgence, add-ons, and late-night occasions lose mix, while health-oriented formats can capture spend with higher lifetime value per customer. That argues the real losers are not just casual dining names, but adjacent suppliers tied to foodservice volume and promotional intensity.

For fitness, the upside is less about spontaneous gym enthusiasm and more about retention. Weight-loss drug users often need a durable behavior loop to preserve results, which benefits low-cost, high-frequency operators with simple value propositions and broad accessibility. That makes the demand shift more defensible for PLNT than for premium boutique concepts, because the former can monetize the new cohort without requiring a large increase in discretionary spend per visit.

The key timing issue is that the selloff in affected restaurant names may be front-running a multi-year adoption curve, but the earnings impact will likely unfold unevenly over 12-24 months as oral formulations improve access and adherence. The contrarian risk is that markets may be overpricing a linear cannibalization story: many consumers will offset lower restaurant calories with higher spend on protein-heavy menu items, supplement products, or occasion-based dining, so the true damage may be margin pressure rather than outright volume collapse. That suggests the trade should favor relative value over outright sector shorts.

A more subtle winner set includes companies exposed to home fitness equipment, protein snacks, and weight-management services, while the broader consumer staples basket may see mix shifts toward higher-protein, lower-sugar offerings. If gym utilization rises, landlords with fitness-heavy retail tenants could also benefit through stickier occupancy and lower churn. The biggest reversal catalyst would be disappointing long-term adherence or pricing/access friction that slows GLP-1 penetration; absent that, the trend should remain incremental but durable.

Key Decisions for Investors

• Maintain a tactical short bias in CMG over the next 3-6 months; use any relief rally to sell into strength, with the thesis that traffic softness and menu reconfiguration will cap same-store sales recovery.
• Go long PLNT on a 6-12 month horizon as a beneficiary of GLP-1-driven behavior change; target upside from earnings durability and member growth, with downside limited if category adoption stalls because the valuation is supported by a recurring model.
• Pair trade: long PLNT / short CMG for a relative-value expression of the obesity-drug thesis; this isolates the consumer-spending shift while reducing market beta and macro noise.
• Consider a basket long in health-oriented consumer names and protein adjacencies over the next 12 months; the best risk/reward is in companies that can capture mix shift without needing dramatic unit growth.
• For options, buy medium-dated puts on restaurant names with high traffic sensitivity if implied vol remains cheap; the catalyst window is 1-2 quarters, when management commentary should start reflecting persistent mix and frequency pressure.